Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib by Ding, Pei N. (S33008) et al.
OR I G I N A L A R T I C L E
Plasma next generation sequencing and droplet digital PCR-
based detection of epidermal growth factor receptor (EGFR)
mutations in patients with advanced lung cancer treated
with subsequent-line osimertinib
Pei N. Ding1,2,3,4 , Therese Becker1,2,4, Victoria Bray1,3, Wei Chua1,3, Yafeng Ma1,4, Bo Xu5,
David Lynch1,2, Paul de Souza1,2,3,4 & Tara Roberts1,2,4
1 Centre for Circulating Tumor Cell Diagnostics & Research, Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia
2 School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
3 Medical Oncology Department, Liverpool Hospital, Liverpool, New South Wales, Australia
4 South Western Sydney Medical School, University of New South Wales, Liverpool, New South Wales, Australia
5 Thermofisher Scientific, Scoresby, Victoria, Australia
Keywords
Circulating tumor DNA; droplet digital PCR;
next generation sequencing; plasma
genotyping; resistance mechanisms.
Correspondence
Pei Ni Ding, Ingham Institute for Applied





Received: 12 June 2019;
Accepted: 5 July 2019.
doi: 10.1111/1759-7714.13154
Thoracic Cancer 10 (2019) 1879–1884
Abstract
Background: Gene mutation analysis from plasma circulating tumor DNA
(ctDNA) can provide timely information regarding the mechanism of resistance
that could translate to personalised treatment. We compared concordance rate of
next generation sequencing (NGS) and droplet digital polymerase chain reaction
(ddPCR) in the detection of the EGFR activating and T790M mutation from
plasma ctDNA with diagnostic tissue biopsy-based assays. The second objective
was to test whether putative osimertinib resistance associated mutations were
detectable from plasma using NGS.
Methods: From January 2016 to December 2017, we prospectively collected
plasma samples from patients prior to commencement of second- or third-line
osimertinib therapy and upon disease progression, in a single tertiary hospital in
South Western Sydney, Australia. Amplicon-based NGS and ddPCR assays were
used to detect activating epidermal growth factor receptor (EGFR) and T790M
mutations in 18 plasma samples from nine patients; all patients were required to
have tissue biopsies with known EGFR status.
Results: High concordance of allelic fractions were seen in matched plasma
NGS and ddPCR for activating EGFR mutations and T790M mutations
(R2 = 0.92, P < 0.0001). Using tissue biopsies as reference standard, sensitivity
was 100% for NGS and 94% for ddPCR. Several possible osimertinib resistance
associated mutations, including PIK3CA, BRAF and TP53 mutations, were
detected by NGS in samples upon progression on osimertinib therapy.
Conclusion: ddPCR assays for EGFR mutations appear to be as sensitive and
highly concordant as amplicon-based NGS. NGS has the ability to detect novel
resistance mutations.
Introduction
Mutational analysis of circulating tumor DNA (ctDNA)
represents one of the major breakthroughs in thoracic
oncology in recent years. ctDNA isolation from liquid
biopsies allows identification of cancer-related mutations,
which have significant impact on the management of
patients, especially when tissue biopsy samples are not
readily available. In lung cancer patients with acquired
resistance to first generation epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI), ctDNA
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testing allows a rapid and noninvasive access to identify
the presence of the resistance-associated acquired muta-
tion T790M that predicts response to the third-generation
EGFR-TKI, osimertinib.1 Recent meta-analysis has shown
that T790M can be detected in plasma ctDNA with high
sensitivity and specificity.2 Patients treated with
osimertinib may subsequently develop further mecha-
nisms of acquired resistance and have disease progression
after a median treatment duration of 10 months.3 Liquid
biopsies could be used to monitor and guide treatment
options based on the identification of mechanisms of
acquired resistance.
Current available assays for analysis of plasma ctDNA
are limited by cost, turnaround time and variable accuracy.
The most widely used assay is droplet digital polymerase
chain reaction (ddPCR) which is restricted to detection of
known mutations and the limited capability of detecting
only one mutation per assay. Next generation sequencing
(NGS) of ctDNA is attractive due to its potential to more
broadly detect multiple tumor specific genetic changes.
Although whole genome NGS is still challenging for
ctDNA, amplicon-based NGS targets specific disease
related genetic hotspots4 and is the basis for the tumor
NGS assay that recently received approval by the US FDA
(Oncomine Dx Target, ThermoFisher). Here, we compared
ddPCR and amplicon-based NGS for detection and moni-
toring of driver and resistance mutations from ctDNA of
advanced EGFR+ NSCLC patients. We propose that NGS
will be useful for broader assessment of resistance mecha-
nisms for patients who have progressed on osimertinib,
while ddPCR assays have a role in monitoring disease
response and progression.
Methods
Nine patients with advanced EGFR+ T790M+ NSCLC and
tissue biopsies available for evaluation were consented for
plasma collection at Liverpool Hospital, Australia under
approved Human Research ethics committee protocols
(Project number 13/097, HREC/13/LPOOL/158). A total of
18 plasma samples were collected for analysis prior to
commencement of osimertinib, and at the time of disease
progression on osimertinib. Radiological imaging was per-
formed to assess disease response to treatment at three and
six months as per local treatment guidelines, with subse-
quent scans performed as per treating clinician’s discretion.
Plasma analyses were blinded to clinical data.
Statistical concordance of mutant allelic fraction (MAF)
between plasma ddPCR and NGS was calculated using
Kendall concordance coefficient. Sensitivity for plasma
ddPCR and plasma NGS assays was calculated with refer-
ence to available tumor biopsy genotype.
Plasma collection and ctDNA extraction
Peripheral blood samples were collected in 9 mL EDTA
vacutainer tubes at the above time points. Plasma was
processed within two hours and involved a first centrifuga-
tion step of 800 g for 10 minutes and a second spin of
13 000 rpm for 10 minutes. Plasma was stored at −80C
until ctDNA extraction using the QIAmp Circulating
Nucleic Acid Kit (Qiagen) according to the manufacturers’
instructions. ctDNA was eluted in 20 μL per mL of input
plasma and stored at −20C until further analysis.
Droplet digital PCR (ddPCR)
ddPCR was performed using Bio-Rad QX200 Droplet Digi-
tal system (BioRad Laboratories) for all samples at our cen-
tre with methods described previously.5,6 Primers and
probes were generated to detect EGFR-L858R, -S768I,
-L861Q, -T790M and the corresponding wild type
(WT) amplicons as well as the EGFR exon 19 deletion
using the QX200 BioRad droplet digital PCR (ddPCR)
suite (BioRad, Gladesville, Australia). The assays were
optimised for annealing temperatures combined with Bio-
Rad’s recommended primer and probe concentrations and
standard droplet digital PCR (ddPCR) protocol. Detected
mutant and wild type copy numbers were normalised
based on the volumes of plasma used for DNA extraction,
elution and the input into the ddPCR reaction (DNA
copies/mL plasma) based on the following formula:
Events× 20
Input ctDNA volume μLð Þ ×
Elution volume μLð Þ
Plasma volume μLð Þ
The ddPCR threshold for positive mutant detection was
set at two or more positive droplets (≥10 mutant
copies/mL of plasma) to ensure specificity. The sensitivity
of our ddPCR assay allowed for the detection of a mutant
allele fraction of 0.1% or more (i.e., one mutant molecule
in a background of 1000 wild type molecules).
Plasma next generation sequencing (NGS)
The DNA panel of Oncomine Lung cfTNA Research Assay
kit (Thermo Fisher Scientific, Waltham, MA, USA) was
used for this study targeting 11 genes with 174 hotspot
SNVs and indels, including ALK, BRAF, EGFR, ERBB2,
KRAS, MAP2K1, MET, NRAS, PIK3CA, ROS1, and TP53.
ctDNA were quantitated using Qubit dsDNA HS Assay Kit
(Thermo Fisher Scientific). Tag Sequencing technology was
employed to amplify regions of interest. Sequencing librar-
ies were prepared with Oncomine Lung cfTNA Research
Assay kit (Thermo Fisher Scientific) following the manu-
facture’s protocol using 20 ng of DNA to achieve 0.1%
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limit of detection (LOD); then libraries were quantified by
qPCR with Ion Library TaqMan Quantitation Kit (Thermo
Fisher Scientific). Libraries with concentration ranging
from 154 to 2364 pM were obtained and normalized to
25 pM. Five to six normalized libraries were pooled
together, templated on Ion Chef System, loaded onto Ion
520 Chips, then sequenced on Ion S5 XL sequencer. Reads
were mapped back to the designed target regions supplied
by the manufacturer automatically by using Oncology-
Liquid Biopsy workflow on Torrent Server with Torrent
Suite software version 5.6 (Thermo Fisher Scientific). Vari-
ants were called using default set parameters of Oncomine
Lung Liquid Biopsy - w1.3 - DNA - Single Sample 5.6
workflow on local Ion Reporter Server (Thermo Fisher Sci-
entific) at IR5.6.
Results
Patient and disease characteristics
A total of 18 paired plasma samples from nine patients
were collected before commencement on osimertinib and
post-osimertinib resistance. All patients had been previ-
ously diagnosed with EGFR+ advanced NSCLC with tissue
biopsy testing being positive for common and uncommon
EGFR mutations. Tissue histopathology and EGFR muta-
tion testing were performed as part of the routine diagnos-
tic testing by the anatomical pathology laboratory at
Liverpool Hospital, NSW, Australia. The therascreen EGFR
RGQ PCR kit (Qiagen, Hilden, Germany) was used with
targeted ARMS (amplification refractory mutation system)
technology to detect mutations in exon 18–21 of the EGFR
gene. All patients had lung adenocarcinoma histological
subtype. All patients had a minimum of two sites of extra-
cranial metastatic disease (range 2–5 sites). Other patient
characteristics are shown in Table 1.
All patients were treated with first generation EGFR-TKI
gefitinib or erlotinib with a median duration on treatment
of 10.8 months (range 5.4–34.2 months). Upon radiological
disease progression, 4/9 (44%) patients had repeat tissue
biopsy with none showing histological transformation to
small cell lung carcinoma. All patients had an EGFR-
T790M mutation detected on tissue or plasma biopsy and
were treated with osimertinib at a standard daily dose of
80 mg. Median duration of treatment with osimertinib was
7.3 months (range 2–19 months). At the first radiological
assessment of response to treatment, 5/9 (56%) patients
had a partial response with 4/9 (44%) showing radiological
evidence of disease progression. 5/9 (56%) patients received
chemotherapy post-osimertinib and 3/9 (33%) had best
supportive care only. One patient was continued on
osimertinib upon disease progression with stable disease
on subsequent scans. At the time of data cutoff, 77% (7/9)
patients had died. Median PFS was seven months (range
1–15 months) and median OS was 12 months (range
2–22 months). Figure 1 summarises the duration of subse-
quent treatment and survival for each patient.
High concordance and sensitivity
in detecting known EGFR mutations
We observed a correlation between quantification of total
cell-free DNA (cfDNA) quantity (measured by Qubit) and
the detected concentration of WT cfDNA for EGFR
(R2 = 0.81, P < 0.0001, Fig 2a). Quantitative concordance
of allelic frequency (AF) between NGS and ddPCR was
high for both EGFR activating and T790M mutations
(R2 = 0.92, P < 0.001, Fig 2b). Pre-existing diagnostic acti-
vating EGFR mutation in tissue biopsy was used as a refer-
ence standard to determine sensitivities of plasma NGS
and ddPCR across the 18 plasma samples. Sensitivity for


















1 M Ex-smoker 3 Asian L858R 3 L858R (3.2%) TP53 G245D (0.14%)
2 F Ex-smoker 6 Asian L858R 5 L858R (2.7%) None detected
3 M Smoker 8 Caucasian L858R 5 L858R (82.7%) TP53 R273H (24%)
4 M Non-smoker 5 Caucasian L858R 4 L858R (31.8%) PIK3CA
H1047R (24.4%)
5 F Non-smoker 11 Asian L858R 2 L858R (0.25%) TP53 G154T (0.15%)
6 F Non-smoker 14 Asian Del19 3 Del19 (4.13%) TP53 C277Y (0.09%)
7 F Non-smoker 4 Asian Del19 2 PIK3CA
E542K (1.1%)
BRAF V600E (0.08%)
8 F Ex-smoker 1 Caucasian S768I/G719S 4 G719S (3.2%) None detected
9 M Smoker 2 Asian L861Q 4 L861Q (5.8%) None detected
F, female; M, male.
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detection of the driver EGFR mutation was 100% (18/18)
for NGS and 94% (17/18) for ddPCR.
Detection of resistance mutations to
osimertinib with plasma NGS
We investigated resistance mechanisms in nine
osimertinib-treated patients with detectable EGFR driver
mutations with plasma NGS on paired plasma samples
(pre- and post-treatment resistance with osimertinib,
Table 1). Four patients (44%) developed new TP53 muta-
tions (G245D, C277Y, R273H, G154T). Two patients
(22%) developed PIK3CA mutations (H1047R, E542K).
We also detected the BRAF V600E mutation in the plasma
of one patient at disease progression. Three patients (33%)
had detectable T790M in the plasma at disease
progression.
Two patients had uncommon EGFR mutations (S768I
and L861Q) but there is little data currently to predict
whether these patients will respond to third generation
EGFR-TKIs. In our study, both these patients had disease
progression within the first three months of treatment with
osimertinib. Interestingly, no new mutations were identi-
fied with the lung panel NGS at disease progression in the
two patients with these mutations, suggesting that these
uncommon EGFR mutations may predict for primary
resistance to osimertinib.
Discussion
Plasma amplicon-based NGS is a relatively new technol-
ogy, while ddPCR is now firmly established for ctDNA
based biomarker detection. Our study demonstrated high
sensitivity and quantitative concordance of amplicon-based
plasma NGS when compared with ddPCR to detect EGFR-
activating and resistance mutations.
Both methods are attractive for specific settings using
ctDNA. Compared to NGS, ddPCR is proposed to have
higher sensitivity down to 0.001%.7 Further, it has an easier
set-up process, faster turnaround time, and does not
require complex informatics support for analysis. However,
only known genetic changes can be detected, and the
potential for multiplex detection of several biomarkers is
limited. In contrast, NGS may identify any genetic changes
in the entire target regions screened, including novel

























Figure 1 Treatment duration and survival outcome of patients. Swim-
mer plot indicating treatment types and duration that patients received
and survival outcome. All patients were started on osimertinib after dis-
ease progression with first-generation EGFR TKI or chemotherapy. ( )
Osimertinib, ( ) Chemotherapy (carboplatin/gemcitabine), ( ) Nivolumab,
( ) BSC, ( ) Disease progression, ( ) Death and ( ) Ongoing therapy.
Figure 2 (a) High concordance between Qubit reading and WT allele concentration (R2 = 0.81). WT, wild type. (b) Concordance EGFR mutation
detection ddPCR versus NGS. A total of 18 samples from nine patients were analysed with both ddPCR and NGS to assess EGFR mutations. There
was high quantitative concordance (R2 = 0.92) of the mutant alleic frequency (MAF) across 36 EGFR variants (activating: L858R, exon 19 deletion,
L861Q, S768I and T790M resistance mutation) from 18 samples detected both with plasma NGS and plasma ddPCR. NGS, next generation sequenc-
ing; ddPCR, droplet digital polymerase chain reaction; MAF, mutant allelic frequency. ( ) EGFR activating mutations, and ( ) EGFR T790M.
1882 Thoracic Cancer 10 (2019) 1879–1884 © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd
NGS and ddPCR to detect plasma EGFR mutations P.N. Ding et al.
mutations. Testing of many genetic regions simultaneously
is common with NGS. However, NGS is more time-con-
suming, more costly, and requires more complex informat-
ics support for data analysis. A recent study has shown
that amplicon-based NGS technology could also be used to
detect chromosomal rearrangement and fusion genes in
ctDNA from NSCLC patients with high sensitivity and
specificity.8
Our study has added to the current knowledge on the
potential mechanisms of acquired resistance to osimertinib.
In our patient cohort, we detected the previously reported,
and likely resistance-associated changes, BRAF V600E and
PIK3CA using plasma NGS9. We have not detected other
secondary EGFR mutations such as C797 and L792 or C-
MET amplification which were reported to be present in
26% and 14% of cases respectively10 likely due to the sam-
ple size. There were four cases of acquired TP53 mutations
at the time of osimertinib resistance, with patient 3 reaching
a very high allelic frequency of 24% (Table 1). TP53 muta-
tion is commonly detected in human cancers and its prod-
uct is a multifunctional protein that regulates several
physiological processes including cell cycle checkpoints,
apoptosis and DNA repair.11 Currently, there is limited
knowledge regarding the role of mutant p53 in osimertinib
resistance or the mechanism involved. A previous study in
triple negative breast cancer suggested that mutant p53
may be linked to endosomal recycling of EGFR and
integrin to the membrane, leading to increased proinvasive
abilities of cancer cells.12 Functional studies are necessary
to clarify if TP53 mutations detected here indeed alter
EGFR levels, or whether its proapoptotic role is crucial for
osimertinib induced cell death with the implication that
mutations may lead to osimertinib resistance in NSCLC.
It was interesting that no new potential resistance muta-
tions were identified for two patients with EGFR S768I and
L861Q activating mutations using the lung panel NGS at
the time of disease progression, and that both patients
showed resistance to osimertinib within three months of
therapy. Pooled data analysis had shown that these muta-
tions predict response to the second generation EGFR-TKI
afatinib,13 but whether these mutations predict sensitivity
to osimertinib is currently unclear. If these mutations are
the cause of the primary resistance to osimertinib, it would
be important to clarify this by functional in vitro assays to
guide treatment decision for patients with these uncom-
mon EGFR mutations in the future.
The main limitation of this exploratory study is the
small number of patients included. Larger studies will be
needed to validate the findings from this study. Nonethe-
less despite the small number, this study adds to the evi-
dence that NGS and ddPCR have high concordance and
accuracy in detecting EGFR sensitizing and resistance
mutations in lung cancer patients. This study also showed
that new mutations could be detected in the plasma of
almost all patients who developed acquired resistance to
osimertinib. We acknowledge that the patients in this study
were heterogenous and it is possible that the patients’ clini-
cal characteristics (e.g., ethnicity, smoking status and treat-
ment prior to osimertinib) may affect treatment outcome
and pattern of acquired resistance to osimertinib. A previ-
ous meta-analysis showed that patients with exon 19 dele-
tions, never smokers and female have better treatment
outcomes with EGFR-TKI.14 There is also preliminary data
which showed that the pattern of acquired resistance is dif-
ferent when osimertinib is used in first-line setting15 com-
pared with second-line setting or beyond. Subgroup
analyses (e.g., Asian vs. Caucasian; smokers vs. non-
smokers) could not be performed in this small study and
should be investigated in a larger study to investigate the
difference in pattern of acquired resistance to osimertinib
based on different clinical characteristics. Nonetheless this
heterogeneous group of patients represents the real-world
demographic of patients with EGFR-mutant NSCLC in a
large tertiary hospital in South Western Sydney which con-
tains an ethnically diverse population.
This small study has also highlighted one of the most
important issues of whether commercially available NGS is
ready to be integrated into routine clinical practice. One of
the main advantages of characterisation of the resistance
mutations is the potential this has to open up new treat-
ment options including clinical participation for patients
when the current treatment fails. We acknowledge that
drug access varies in differing parts of the world; however,
there are targeted treatments currently available in clinical
practice for some of the mutations identified in our study
including BRAF V600E. Conversely, for the four patients
with acquired TP53 mutations, whilst there are no targeted
therapeutics currently available, the knowledge of the pres-
ence of this abnormality may facilitate potential clinical
trial participation. Clinical treatment paradigms will con-
tinue to evolve with more complete understanding of p53
biology and continued work as to how to optimally target
aberrant p53 function. Further, knowledge of TP53 muta-
tion status may help to risk stratify patients in the future
and may help for treatment selection similar to the story of
chronic lymphocytic leukemia with TP53 abberations.16
Longer term follow-up results from large prospective stud-
ies which include molecular profiling with NGS for treat-
ment selection will guide clinicians in determining the
clinical utility of NGS in the management of solid tumors.
Conclusion
While the amplicon-based plasma NGS assay provided
coverage of the 11 major targetable gene alterations, spe-
cific alterations were confirmed by ddPCR results in almost
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all cases, suggesting similar performance and accuracy of both
these technologies. With the increase in accessibility of both
technologies, we suggest that they may have complementary
roles in diagnosis and treatment monitoring in metastatic can-
cer, depending on clinical questions at hand, cost, accessibility
with appropriate bioinformatics support, and whether
clinically-relevant genetic alterations are known.
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